Business Description
PaxMedica Inc
NAICS : 541714
SIC : 2833
ISIN : US70424C2035
Share Class Description:
MEX:PXMD: Ordinary SharesDescription
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | -2.26 | |||||
| Debt-to-Equity | -0.87 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 3.6 | |||||
| 3-Year EPS without NRI Growth Rate | 5.7 | |||||
| 3-Year FCF Growth Rate | -17.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.38 | |||||
| Quick Ratio | 0.38 | |||||
| Cash Ratio | 0.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -157.9 | |||||
| Shareholder Yield % | -781.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -1964.4 | |||||
| ROA % | -497.44 | |||||
| ROIC % | -1457.15 | |||||
| ROC (Joel Greenblatt) % | -3917.69 | |||||
| ROCE % | -1270.25 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.09 | |||||
| EV-to-EBITDA | -0.09 | |||||
| EV-to-FCF | -0.11 | |||||
| Earnings Yield (Greenblatt) % | -1142.73 | |||||
| FCF Yield % | -875.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PaxMedica Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -119.193 | ||
| Beta | 0 | ||
| Volatility % | 83.81 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0 | ||
| 20-Day SMA (MXN) | 15.69 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 15.69 - 15.69 | ||
| Shares Outstanding (Mil) | 10.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PaxMedica Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PaxMedica Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
PaxMedica Inc Frequently Asked Questions
What is PaxMedica Inc(MEX:PXMD)'s stock price today?
The current price of MEX:PXMD is MXN15.69. The 52 week high of MEX:PXMD is MXN15.69 and 52 week low is MXN15.69.
When is next earnings date of PaxMedica Inc(MEX:PXMD)?
The next earnings date of PaxMedica Inc(MEX:PXMD) is 2025-03-01 Est..
Does PaxMedica Inc(MEX:PXMD) pay dividends? If so, how much?
PaxMedica Inc(MEX:PXMD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers